Development of a Novel Anti-CD19 Chimeric Antigen Receptor: A Paradigm for an Affordable CAR T Cell Production at Academic Institutions-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Development of a Novel Anti-CD19 Chimeric Antigen Receptor: A Paradigm for an Affordable CAR T Cell Production at Academic Institutions

Published:2019-03 Issue: Volume:12 Page:134-144
ISSN:2329-0501
Container-title:Molecular Therapy - Methods & Clinical Development
language:en
Short-container-title:Molecular Therapy - Methods & Clinical Development

Author:

Castella Maria,Boronat Anna,Martín-Ibáñez Raquel,Rodríguez Vanina,Suñé Guillermo,Caballero Miguel,Marzal Berta,Pérez-Amill Lorena,Martín-Antonio Beatriz,Castaño Julio,Bueno Clara,Balagué Olga,González-Navarro Europa Azucena,Serra-Pages Carles,Engel Pablo,Vilella Ramon,Benitez-Ribas Daniel,Ortiz-Maldonado Valentín,Cid Joan,Tabera Jaime,Canals Josep M.,Lozano Miquel,Baumann Tycho,Vilarrodona Anna,Trias Esteve,Campo Elías,Menendez Pablo,Urbano-Ispizua Álvaro,Yagüe Jordi,Pérez-Galán Patricia,Rives Susana,Delgado Julio,Juan Manel

Funder

Plan Nacional de I + D + I

ISCIII—Subdirección General de Evaluación y Fomento de la Investigación Sanitaria

Fondo Europeo de Desarrollo Regional

Projecte ARI

European Research Council

Spanish Ministry of Economy-Competitiveness

Catalunya Government

Asociación Española Contra el Cáncer

Beca FERO

ISCIII/FEDER

Obra Social La Caixa-Fundaciò Josep Carreras

Publisher

Elsevier BV

Subject

Genetics,Molecular Biology,Molecular Medicine

Reference33 articles.

1. CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia;Brentjens;Sci. Transl. Med.,2013

2. Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias;Brentjens;Blood,2011

3. Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia;Davila;Sci. Transl. Med.,2014

4. Chimeric Antigen Receptor T Cells against CD19 for Multiple Myeloma;Garfall;N. Engl. J. Med.,2015

5. Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor;Kochenderfer;J. Clin. Oncol.,2015

Cited by 73 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. First-in-classTransactivator-Free, Doxycycline-inducible IL-18-engineered CAR-T cells for relapsed/refractory B-cell lymphomas;2024-01-25

2. ESMO Clinical Practice Guideline interim update on the use of targeted therapy in acute lymphoblastic leukaemia;Annals of Oncology;2024-01

3. Advancing CART therapy for acute myeloid leukemia: recent breakthroughs and strategies for future development;Frontiers in Immunology;2023-11-30

4. Endothelial activation and damage as a common pathological substrate in different pathologies and cell therapy complications;Frontiers in Medicine;2023-11-14

5. The academic point‐of‐care anti‐CD19 chimeric antigen receptor T‐cell product varnimcabtagene autoleucel (ARI‐0001 cells) shows efficacy and safety in the treatment of relapsed/refractory B‐cell non‐Hodgkin lymphoma;British Journal of Haematology;2023-10-31

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3